Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

MLA

Andrés Cervantes, et al. Phase Ib Study Evaluating Safety and Clinical Activity of the Anti-HER3 Antibody Lumretuzumab Combined with the Anti-HER2 Antibody Pertuzumab and Paclitaxel in HER3-Positive, HER2-Low Metastatic Breast Cancer. Jan. 2018. EBSCOhost, https://doi.org/10.1007/s10637-018-0562-4.

APA

Andrés Cervantes, Maria Martinez-Garcia, Florence Joly, Georgina Meneses-Lorente, Maurizio Ceppi, Joan Albanell, Christelle Levy, Christoph Schindler, Iria Gonzalez, Véronique Diéras, Francesca Michielin, Annie Moisan, Celine Adessi, Martin Weisser, Wolfgang Jacob, Andreas Schneeweiss, Jose A. Lopez-Martin, Tomas Racek, Ulrik Lassen, … Juan Miguel Cejalvo. (2018). Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. https://doi.org/10.1007/s10637-018-0562-4

Chicago

Andrés Cervantes, Maria Martinez-Garcia, Florence Joly, Georgina Meneses-Lorente, Maurizio Ceppi, Joan Albanell, Christelle Levy, et al. 2018. “Phase Ib Study Evaluating Safety and Clinical Activity of the Anti-HER3 Antibody Lumretuzumab Combined with the Anti-HER2 Antibody Pertuzumab and Paclitaxel in HER3-Positive, HER2-Low Metastatic Breast Cancer,” January. doi:10.1007/s10637-018-0562-4.